Table 3.

Summary of clinical data used in this work.

Reference	Quantities used in this work	Vaccine	Dosage	Population size
18	RBD IgG, Spike IgG	BNT162b2 &mRNA-1273	2 dose, 30 $\mathrm{\mu }$g or 100 $\mathrm{\mu }$g	33 (32 BNT162b2 & 1 mRNA-1273)
19	Spike IgG	BNT162b2	2 dose, 30 $\mathrm{\mu }$g	124 for dose 1 69 for dose 2
20	Spike-RBD IgG, IFN-$\gamma$,IL-6, IL-8, IL-15, IL-16	BNT162b2	2 dose, 30 $\mathrm{\mu }$g	63
21	Spike IgG, IFN-$\gamma$	BNT162b2	2 dose, 30 $\mathrm{\mu }$g	20
22	RBD IgG	mRNA-1273	2 dose, 100 $\mathrm{\mu }$g	34
25	Spike IgG, RBD IgG	mRNA-1273	2 dose, 25 $\mathrm{\mu }$g	33
23	Spike IgG, RBD IgG	BNT162b2 &mRNA-1273	2 dose, 30 $\mathrm{\mu }$g or 100 $\mathrm{\mu }$g	20 (6 BNT162b2 & 14 mRNA-1273)
24	Spike IgG	BNT162b2	2 dose, 30 $\mathrm{\mu }$g	46 (24 females, 22 males)

Some publications listed studied in-host vaccine dynamics from both Sars-CoV-2 naive and previously infected indivduals, in this work we only digitized those data that are in the naive category and report the associated population size.